Equities analysts expect Adamas Pharmaceuticals (NASDAQ:ADMS) to post $1.68 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Adamas Pharmaceuticals’ earnings, with the highest sales estimate coming in at $2.30 million and the lowest estimate coming in at $1.25 million. The business is scheduled to report its next earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Adamas Pharmaceuticals will report full year sales of $1.68 million for the current financial year, with estimates ranging from $21.70 million to $26.65 million. For the next financial year, analysts expect that the company will post sales of $81.99 million per share, with estimates ranging from $75.00 million to $89.78 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Adamas Pharmaceuticals.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.09). The company had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.84 million. The firm’s quarterly revenue was up 1435.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.68) EPS.
In other news, insider Rajiv Patni sold 1,252 shares of the firm’s stock in a transaction on Wednesday, March 21st. The stock was sold at an average price of $25.94, for a total transaction of $32,476.88. Following the completion of the transaction, the insider now directly owns 21,515 shares in the company, valued at $558,099.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Gregory T. Went sold 4,541 shares of the firm’s stock in a transaction on Wednesday, March 21st. The shares were sold at an average price of $25.75, for a total value of $116,930.75. Following the transaction, the chief executive officer now owns 182,610 shares of the company’s stock, valued at $4,702,207.50. The disclosure for this sale can be found here. Insiders have sold 6,360 shares of company stock valued at $164,138 over the last 90 days. Corporate insiders own 29.00% of the company’s stock.
Several large investors have recently modified their holdings of the company. Macquarie Group Ltd. increased its holdings in shares of Adamas Pharmaceuticals by 18.6% during the fourth quarter. Macquarie Group Ltd. now owns 890,962 shares of the specialty pharmaceutical company’s stock valued at $30,195,000 after acquiring an additional 139,934 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in shares of Adamas Pharmaceuticals by 639.3% during the third quarter. Point72 Asset Management L.P. now owns 850,165 shares of the specialty pharmaceutical company’s stock valued at $17,998,000 after acquiring an additional 735,165 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Adamas Pharmaceuticals by 13.3% during the fourth quarter. Alliancebernstein L.P. now owns 657,737 shares of the specialty pharmaceutical company’s stock valued at $22,291,000 after acquiring an additional 77,303 shares in the last quarter. Emerald Advisers Inc. PA increased its holdings in shares of Adamas Pharmaceuticals by 2.8% during the fourth quarter. Emerald Advisers Inc. PA now owns 542,897 shares of the specialty pharmaceutical company’s stock valued at $18,399,000 after acquiring an additional 14,830 shares in the last quarter. Finally, Deutsche Bank AG increased its holdings in shares of Adamas Pharmaceuticals by 632.7% during the fourth quarter. Deutsche Bank AG now owns 506,369 shares of the specialty pharmaceutical company’s stock valued at $17,159,000 after acquiring an additional 437,263 shares in the last quarter. Hedge funds and other institutional investors own 77.25% of the company’s stock.
ADMS traded down $1.21 during trading on Monday, reaching $22.94. The stock had a trading volume of 621,563 shares, compared to its average volume of 887,768. The company has a current ratio of 10.79, a quick ratio of 10.69 and a debt-to-equity ratio of 1.55. The company has a market cap of $647.39, a price-to-earnings ratio of -5.78 and a beta of 1.59. Adamas Pharmaceuticals has a one year low of $13.50 and a one year high of $44.00.
WARNING: “Zacks: Brokerages Expect Adamas Pharmaceuticals (ADMS) Will Announce Quarterly Sales of $1.68 Million” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3339270/zacks-brokerages-expect-adamas-pharmaceuticals-adms-will-announce-quarterly-sales-of-1-68-million.html.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.